Beckman Coulter Unveils Dual New Product Launches at CACLP 2024 as Part of Danaher’s First-Ever Group-Level Debut in China

Mar 19, 2024 17:04 CST Updated 17:04

Danaher

Product Design and Manufacturer

On March 16, the 21st China International Laboratory Medicine and Blood Transfusion Instrument Reagent Expo (CACLP) grandly opened in Chongqing.

One of the TOP4 global in vitro diagnostics giants, DanaherFirst participation at the group level.

Total area of 450 square metersOn the booth，Danaher1Four operating companies made their full appearance.The six major exhibition areas - Clinical Laboratory Center, Oncology Diagnosis and Treatment Center, Translational Medicine Center, Critical Care Center, Respiratory and Infectious Disease Diagnosis and Treatment Center, and Upstream In Vitro Diagnostic Reagent Development and Production - have achieved full coverage of the in vitro diagnostics field. Danaher CorporationIn Vitro Diagnostics (IVD)The full range of products and solutions in the field are presented in their entirety.

At this feast of the IVD industry, Beckman Coulter, one of the core operating companies of Danaher's medical diagnostics platformThe First Launch of Two New High-End Intelligent ProductsEquipment, this is a further step after the localization of all main models last year.Intensifying efforts in the Chinese market and accelerating localization are also solid implementations of Danaher's "Creating and Elevating China 2.0" strategy.

Chen Xiaosui, President of Danaher China Medical Diagnostics Platform, Global Vice President of Beckman Coulter Clinical Diagnostics, and General Manager of China RegionIndicates:“At this exhibition, Danaher, together with its 14 operating companies, appeared for the first time as a 'new face' in the form of a group.’Debut, Innovation Sets Off Again. Meanwhile, This Year,Danaher Upgrades "Create and Elevate China" Once Again’Strategy, namely 'Dual Innovation Acceleration Engine'’Strategy: We will return to core values, seize unmet medical needs, and establish leadership in the fields of oncology and neurology diagnostics.”

All signs indicate that Beckman CoulterHas started to accelerate in China.

▲ Chen Xiaosui, President of Danaher China Medical Diagnostics Platform, Global Vice President of Beckman Coulter Clinical Diagnostics, and General Manager of China Region

01

A New Milestone in Local Innovative Development: Two New Products Unveiled

When "Foreign Capital Withdraws from China" becomes a topic, Danaher, one of the top four global giants in the in vitro diagnostics industry, demonstrates through action that China remains worthy of continued investment.

"We will continue to increase our investment, deepen exchanges and cooperation with high-quality local partners, bring excellent products and services to a wider range of medical institutions, respond more quickly and effectively to the diversified needs of the Chinese market, and enhance and expand our ability to serve customers and patients." Chen Xiaosui said.

The new products on the booth also convey this concept.

Following the achievement of all high-end main models last year,This year,Beckman Coulter Adds New China-Made Model. At this year's CACLP, Beckman CoulterDebut of Two New China-Made Products——Fully Automatic Sample Processing SystemDxA 5000 Fit、Fully Automatic Biochemical Analyzer DxC 700 AU, while effectively addressing the pain points of China's IVD industry, alsoMarks a new progress in the localization of Beckman Coulter's high-end intelligent equipment produced in China.

▲ Fully Automated Sample Handling System DxA 5000 Fit &Fully Automatic Biochemical AnalyzerDxC 700 AUListed

Fully Automatic Sample Processing SystemDxA 5000 Fit, dedicated to solving many pain points for medical laboratories, such as "complex specimen preparation processes, variability in manual operations, and the significant challenges of standardization and automation."。

Pre-analytical specimen quality assessment function can be performedIdentify More Than 70% of Specimen Quality Issues in 3 Seconds, reduce pre-analytical errors, and improve testing quality;Intelligent workflow design makesTurnaround Time (TAT)Stable and reliable.
Supports multidisciplinary testing as well as various tube types and sizes for specimen collection.Can be connected to immunoassay analyzers, biochemical analyzers, and hematology analyzers., and also construct a variety of product combinations for automated production lines made in China to meet different customer needs.
Small footprint, meetThe needs of small and medium-sized laboratories,It also facilitates the laboratory's future expansion and upgrades.

The fully automatic biochemical analyzer DxC 700 AU is from Beckman Coulter.High-end equipmentMade in ChinaA Heritage of Excellence.

Biochemical analyzers are mainly used for testing clinical biochemical indicators such as liver function, kidney function, blood lipids, diabetes, infections, and rheumatic immunity, thereby providing important scientific evidence for the diagnosis, treatment, and prevention of diseases. They are essential testing equipment in hospitals.

In the fierce track competition of China's biochemical analyzer market, Beckman Coulter has always played a pivotal role.The fully automatic biochemical analyzer DxC 700 AU has quickly gained market favor since its launch, thanks to multiple advantages.

Its main features include:Comprehensive test menu, stable results; Spectrophotometric testing speed can reach 800 tests/hour (up to 1200 tests/hour with electrolytes). Automatic quality control and calibration functions improve operational efficiency. An independent emergency disk ensures priority for urgent tests; reagents and consumables can be loaded without stopping the system. Long-life electrodes are economical and easy to maintain.

The fully automated biochemical analyzer DxC 700 AU can be used either as a standalone analytical device or integrated with laboratory automation systems, offering flexibility that makes it suitable for laboratories of different sizes and needs.

02

Continuously Explore the New Connotations of Localization

In the rules of commerce, whether multinational corporations choose to continue advancing the localization of the Chinese market will inevitably be closely tied to the performance of the Chinese market.

When "localization" becomes a must for foreign enterprises choosing to "remain in China," how to effectively advance localization has become one of the key issues these enterprises need to consider in order to break through.

In recent years, driven by Danaher's "Create and Elevate China" localization strategy, Beckman Coulter's localization has also been advancing in depth in line with the industry's pace. Local production, local R&D innovation, and local collaboration have become the three key focal points for Beckman Coulter in implementing its localization strategy in the Chinese market.

In terms of domestic production,Beckman Coulter has currently achieved localized production for all its main models in China.

In 2023, Danaher Diagnostic Platform's China R&D and Manufacturing Base officially commenced production.BaseAdvanced production technology and intelligent production lineMeet the "Industry 4.0" Standard, to promote Beckman Coulter's rapid realization of local production for all major equipment in China.：In January 2023, the first domestically produced biochemical analyzer AU 5800 in China, Automated Workflow DxA 5000Official delivery;In March, the first reagent production line RPL&8 was put into operation; in August, the first domestically produced immune analyzer Dxl 800 was officially delivered.

At this year's CACLP, the fully automated sample processing system DxA 5000 Fit and the fully automated biochemical analyzer DxC 700 AU also completed their China-produced market launch.

In the future,Beckman Coulter is expected to accelerate the process of producing more reagents in China.

In terms of local R&D innovation,Beckman CoulterIn line with the trend of intelligence,Created a comprehensive digital and intelligent solution, integrating data analysis into the construction of smart laboratories, fully exploring the value behind the data, and improving the accuracy of test data and production efficiency.

Newly Put into Operation Danaher Diagnostic PlatformDeveloped in ChinaManufacturing BaseWhile completing more localized production in China, shorten the time from product development to market launch, help bring products to market more quickly, better seize market opportunities, and increase market share.

The "synergistic effect" of叠加 Danaher's diagnostic platform andYears of cutting-edge technology experience, Beckman Coulter will have stronger innovative potential。

In terms of local cooperation,Beckman Coulter is increasingly engaging in open-ended localized cooperation in China, exploring solutions to meet the needs of medical institutions at all levels by leveraging the resource advantages of channels and service providers in terms of product innovation, innovations in the distribution sector, business model innovation, and more.

It should be noted that, at Beckman Coulter,Local production, local R&D innovation, and local collaboration do not evolve independently but are intertwined and mutually reinforcing. In the process of promoting technological innovation and industrial development, it is essential to fully leverage the strengths and roles of all parties to achieve collaborative cooperation, thereby better driving the continuous growth and expansion of the entire industry chain.

03

Local Strategy Upgrade! Beckman Coulter Takes a Bigger Step

At the beginning of 2022,The Fully Launched "Create and Elevate China" Strategy, makingDanaher ChinaChina Market Continues to Advance the Localization of Manufacturing & Supply Chain, Commercialization, and Innovation, Eventually Forming a "Flywheel". This Flywheel is Accelerated by the Danaher Business System (DBS), Aiming to Become a "Truly Localized Multinational Enterprise" that Can Respond and Make Decisions Quickly to Various Events.

While fully practicing local production, local R&D innovation, and continuously promoting local cooperation,2023During the CIIE in November, Danaher announced"Create and Elevate China" Local Strategy 2.0Version, officially ushering in a new phase of localization.

Innovation is at the core of "Create and Elevate China 2.0." Specifically, the "Dual Innovation Acceleration Engines" focus on fostering innovation in medical institutions and empowering enterprises in industrial parks. The initiative aims to integrate the policy chain, industry chain, talent chain, innovation chain, capital chain, and ecosystem chain, thereby driving innovation within China's healthcare ecosystem.

At the group level, Danaher returns to its core values, addresses unmet medical needs, and establishes leadership in the diagnosis of cancer and neurological diseases, including Alzheimer's.

Guided by this strategy, Beckman Coulter will accelerate its localization efforts in China with greater intensity, continuously expanding the boundaries of localization. This aims to stimulate new models and momentum, further developing "new quality productivity" within China, and responding more swiftly to the demands of the Chinese market.

CACLP New Exhibition Model, First Product Launch, and Localization Progress: At the Start of 2024, Beckman Coulter Commercial Enterprise (China) Co., Ltd. Achieved a Perfect Beginning.

At Danaher CorporationThe first brand-new year of global strategic focus and brand renewal, at Danaher "Create and Elevate China"Entering the crucial year of 2.0, Beckman Coulter will vigorously expand its presence in the Chinese market with the support of the group, fully implementing its localized strategy!"

· END ·

--Featured Recommendations--